Compound Screening and Drug Development

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Compound Screening

Drug Development

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.

Compound Screening

Compound Screening Marketing Assay Development Drugs

Target-directed cancer: protein-ligand interactions

Drug Target Review

NOVEMBER 1, 2023

Can you elaborate on how these techniques are integrated into your research process and how they contribute to advancing cancer drug discovery? We need to build the assays that we need for compound screening. In 2019 he became Reader in Structural Biology and Cancer Drug Discovery.

Fragment Screening

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays

Drug Discovery Digest

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

Target-directed cancer: protein-ligand interactions

Stay Connected